| atrial fibrillation | All results are NS for efficacy inferior to placebo in terms of Withdrawals due to adverse effects in ASAP, 2003 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ASAP, 2003 | vs placebo | | Withdrawals due to adverse effects 2.30 [1.20; 4.39] | all cause mortality 1.23 [0.38; 3.99] Pro-arrhythmia 6.04 [0.78; 46.62] |
| Trial | Treatments | Patients | Method |
|---|
| ASAP, 2003 | Azimilide various doses (35 to 125 mg/d) after pharmacological or electrical cardioversion (n=891) vs. placebo (n=489) | patients with previous AF documented in the last 2 years | double blind Parallel groups Sample size: 891/489 Primary endpoint: FU duration: 6 months |
|
| post myocardial infarction | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ALIVE, 2004 | vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| ALIVE, 2004 | azimilide 100 mg (n=-9) vs. placebo (n=-9) | post-MI patients with depressed LVF | double blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 1y |
|
